WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > AbbVie
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
WuXi AppTec | January 09, 2017
AbbVie (NYSE: ABBV), a global biopharmaceutical company, life-sciences startup Genomics Medicine Ireland Limited (GMI), and WuXi NextCODE, the global contract genomics organization, today announced the launch of a long-term strategic alliance to conduct population genomics research in Ireland aimed at advancing the discovery and development of novel therapeutic approaches to a range of serious diseases. The 15-year collaboration will focus on major chronic diseases within oncology, neuroscience ...
fiercepharma | January 04, 2018
It's not just specialty drugmakers raising prices in recent days. Big Pharma has pushed through a spate of increases, and while all of them are sub-10% the cap some companies have adopted—some of them will cost payers and consumers plenty. A single price increase, in fact, could add more than $1 billion to the U.S. healthcare system's drug bill this year, one analyst figures: AbbVie's 9.7% hike on its megablockbuster Humira. Wells Fargo's David Maris and his team dug into M...
PharmTech | March 21, 2018
"There are significant knowledge gaps about multiple myeloma, and among these gaps is the role of genetic mutations in response to treatment, and the related outcomes for patients," said Brian G.M. Durie, MD, IMF chairman, in a company press release. "This study has the potential to provide valuable real-world evidence that can help advance care for patients, and we are proud to join forces with AbbVie to further advance efforts in research and education in multiple myeloma."...
fiercepharma | March 26, 2018
Despite resistance from top pharma companies, shareholders are set to vote this spring on resolutions seeking more information about potential links between executive pay and rising drug prices. Several drug industry players resisted the proxy vote, but the SEC ruled in favor of the Interfaith Center on Corporate Responsibility, which filed the resolutions last year. AbbVie, Amgen, Biogen, Bristol-Myers Squibb and Eli Lilly shareholders now have the right to vote on them, ICCR said. The group ha...
Article
PHARMACY MARKET
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE